Introduction {#Sec1}
============

In 2012 more than 500,000 women worldwide were diagnosed with epithelial ovarian cancer (OC) or endometrial cancer (EC) \[[@CR1]\]. OC is the most lethal gynecologic malignancy, with 238,719 cases reported worldwide in 2012, corresponding to 3.4% of all cancer \[[@CR1]\].

OC is an heterogenous disease with at least five sub-types. The biomarker CA125 can detect the most common late stage high-grade serous cancer, but lack diagnostic power for early stage and the less common ovarian adenocarcinomas, especially mucinous cancer. Also, CA125 often result in false positive results in inflammatory diseases such as endometriosis and is not regarded appropriate for fertile women, i.e. those aged 50 or below. The risk of ovarian malignancy algorithm (ROMA) is based on CA125, HE4 and menopausal status to assign women with adnexal ovarian mass into high-risk and low-risk groups. Cut-off for ROMA was estimated at a set specificity of 0.75 and has a sensitivity of 0.94 \[[@CR2]\]. In the hands of specialists, transvaginal ultrasound (TVU) assessment can out-perform ROMA, but these specialized units are very scarce, while a serum test can be easily performed. The multivariate index assay Overa^®^, based on five plasma proteins, can distinguish between benign tumors and OC with a sensitivity of 0.69 and specificity of 0.91 \[[@CR3]\]. Additional plasma biomarkers have been described but not yet clinically evaluated \[[@CR4], [@CR5]\]. The Risk of Ovarian Cancer Algorithm (ROCA) estimates the changes in annual CA125 measurements to identify women with high-risk scores in a screening population and refer these to specialized units for TVU examination. Use of ROCA followed by TVU has been shown to result in an increase in the number of women with OCs detected than using of a fixed cutoff for CA125, with half of these women detected by ROCA prior to CA125 \> 35 and the other half at the same time as CA125 \> 35 \[[@CR6]\]. The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) has reported a reduction in ovarian cancer deaths, excluding prevalent cases, using annual screening using ROCA followed by TVU for ROCA positive subjects \[[@CR7]\].

EC is the most frequent gynecologic malignancy in the developed world and in 2012 affected 319,605 women, corresponding to 7.1% of all cancer \[[@CR1]\]. EC is diagnosed in early stage and have high 5-year survival due to early typical symptoms, such as post-menopause bleedings. Women with EC go through hysterectomy, bilateral salpingoophorectomy and after risk stratification, pelvic lymph node resection. Imaging techniques like CT, MRI and PET have shown variable performance in predicting the depth of EC, myometrial growth, cervical invasion and lymph node metastases \[[@CR8]\]. The histopathology does not reliably reflect the underlying molecular nature of the tumors and more than 20% of tumors that were first classified as non-aggressive later develop into metastatic cancer \[[@CR9]\]. Candidate plasma protein biomarkers have been described for EC, but in clinical practice preoperative biomarkers are lacking to stratify EC patients for lymph node resection, and to high-risk and low-risk groups for recurrence \[[@CR10], [@CR11]\].

For OC there is a strong need to identify proteins for differential diagnosis of suspicious ovarian tumors, early stage detection and sub-type specific diagnosis as complements to HE4 and CA125, in order to refer women to specific imaging techniques, reduce overtreatment and identify women with ovarian malignancy. For EC, biomarkers are needed for stratification of patients to different surgical interventions. In this study, we have used the proximity extension assay (PEA) to identify plasma proteins with a higher sensitivity and specificity that could be used to address the diagnostic needs for the two cancer types.

Materials and methods {#Sec2}
=====================

Clinical material and ethics approval {#Sec3}
-------------------------------------

The plasma samples of women with ovarian and endometrial tumors were from the UCAN collection at Uppsala Biobank, Uppsala University (UU), and the Gynecology tumor biobank at Sahlgrenska University Hospital (SU) (Table [1](#Tab1){ref-type="table"}). All tumors were examined by a pathologist specialized in gynecologic cancers for histology, grade and stage according to International Federation of Gynecology and Obstetrics (FIGO) standards. Plasma samples from women with an indication of adnexal ovarian mass based on TVU and that received a diagnosis of benign conditions, including simple cysts (inclusion cysts, rete ovarii cysts, mesonephric cysts), follicle and corpora luteum cysts, endometriosis, teratoma and benign adenoma, were included as benign tumors. The plasma samples from healthy population controls were from women participating in The Northern Sweden Population Health Study (NSPHS) and from controls in the UCAN collection (Table [1](#Tab1){ref-type="table"}). All plasma samples were frozen and stored at − 70 °C until used in the study.Table 1Baseline information for women included in the discovery and replication stepsDiscoveryReplicationBenign tumors cohort IOvarian cancer cohort IEndometrial cancer cohort IPopulation controls IBenign tumors cohort IIOvarian cancer cohort IIOvarian cancer cohort IIIEndometrial cancer cohortPopulation controls IINumber of women150 (SAL1)106 (SAL1)74 (SU1)399 (NSPHS)76 (SU2)160 (SU2)120 (UU)228 (UU)57 (UU)*Age*Mean59.861.259.8449.360.861.860.966.857.3Median606060496363626858Range16--8828--8829--8614--9422--8819--8721--8629--9018--86SD15.812.910.7597420.314.511.912.910.514.2P-value versus benignNA0.8700.0036652.22E−08NA0.8680.9370.0010.163EthnicityCaucasianCaucasianCaucasianCaucasianCaucasianCaucasianCaucasianCaucasianCaucasian*Stage*I (I/IA/IB)4650 (0/41/9)3510109 (3/83/23)II (II/IIA/IIB)88 (8/0/0)9313 (12/0/1)III (III/IIIA/IIIB/IIIC/IIIC1/IIIC2)4710 (0/2/2/0/2/4)964022 (1/4/4/5/1/7)IV (IV/IVA/IVB)56 (2/0/4)192411 (5/0/6)Classification unvailable14373

Plasma protein measurements {#Sec4}
---------------------------

The abundance of 441 unique protein in plasma were analyzed using the Olink Multiplex assays CVD II, CVD III, INF I, ONC II and NEU I (<http://www.olink.com>) and quantified by real-time PCR using the Fluidigm BioMark™ HD real-time PCR platform as described earlier \[[@CR12]\]. Briefly, for each protein a unique pair of oligonucleotide-labeled antibody probes bind to the targeted protein, and if the two probes are in close proximity a PCR target sequence is formed by a proximity-dependent DNA polymerization event and the resulting sequence is subsequently detected and quantified using standard real-time PCR. Data is then normalized and transformed using internal extension controls and inter-plate controls, to adjust for intra- and inter-run variation as described earlier \[[@CR12]\]. The final assay read-out is given in Normalized Protein eXpression (NPX), which is an arbitrary unit on log2-scale where a high value corresponds to a higher protein expression. Each PEA measurement has a lower detection limit (LOD) calculated based on negative controls that are included in each run, and measurements below LOD were removed from further analysis. All assay characteristics including detection limits and measurements of assay performance and validations are available from the manufacturers webpage (<http://www.olink.com>). The analyses were based on 1 μL of plasma for each panel of 92 assays. To avoid batch effects, samples from the different disease entities and cohorts, including benign tumors, were randomized across assay plates. Each plate included internal controls, as described previously used to adjust for technical variation and/or sample irregularities.

Development of focused multiplex PEA panels {#Sec5}
-------------------------------------------

The focused PEA assays were designed to be compatible with the Fluidigm 192 × 24 Integrated Fluidic Circuit (IFC) which can measure up to 24 assays on 192 samples simultaneously. Hence, 21 protein marker assays and three internal controls for run QC (Incubation Control, Extension Control and Detection control) can be analyzed per IFC. The main difference between the focused assays and the discovery assays is that the focused assays allow higher PEA probe concentration, which in turn means that higher levels of antigen can be measured without reaching the hook in the measuring range (i.e. too much antigen will decrease signals in a homogenous immunoassay format). This modification allowed inclusion of PEA assays from the CVD III panel, where samples are normally diluted 1:100 before analysis, into the focused assays used to analyze undiluted samples, making the differences in protein concentration to be measured more than 7 logs.

Statistical methods {#Sec6}
-------------------

All calculations were carried out in R version 3.2.3 (R core team) \[[@CR13]\]. Individual protein levels were also normalized by plate and sampling round using the MDimNormn-package \[[@CR14]\]. This was done separately for the discovery and replication cohorts.

Significance levels for comparison of protein levels between cases and controls in the discovery cohort were calculated using the two-sided rank-based Spearman test (Wilcoxon). From the entire discovery-cohort, the top-ranking proteins for each of the two cancers was identified based on the *p* value in the comparison of benign tumors to cancer samples. 15 proteins were selected for association with OC and 16 with EC out of which 4 overlapped. Lasso and Elastic-Net Regularized Generalized Linear Models ('glmnet' package in R) was used to fit multivariate models for each cancer using the selected proteins. These models were then evaluated based on the best point and their specificity at a fixed sensitivity of 0.95. This was repeated for each of the tumor/control combination investigated.

A few proteins overlapped between the two cancers, and a total of 27 proteins were selected to be characterized in the replication cohort using focused PEA-panels.

Model performance was evaluated by randomly splitting the observations in the replication cohort into a training set (75%) and a test set (25%). A model was then built using the training set and with the same proteins as selected from the discovery-cohort. The multivariate models were retrained in the replication cohorts using the 'lm' function in R. The reason for re-building the model in the replication data set is that the scaling of the NPX-values can differ between the multiplex PEA panels. This model was then used to predict the response variable in the test set. The random-split into training and test set will often result in different performance due to the limited sample-size. To accommodate for this, a cross-validation schema was applied and the process was repeated 100 times and model prediction errors on the training and test set were recorded. Sensitivity and specificity from the replication were reported as mean ± 1 SD of the 100 runs.

Results {#Sec7}
=======

Discovery step analyses {#Sec8}
-----------------------

The protein biomarker panels were identified using a two-step study design (Fig. [1](#Fig1){ref-type="fig"}). First, the levels of 441 individual proteins was measured in pretreatment plasma collected at time of diagnosis from women with OC or EC and compared to benign tumors and population controls (Table [1](#Tab1){ref-type="table"}). No difference was found in the mean age of women with benign tumors and OC (stage I--IV) or between healthy controls and women with OC (Table [1](#Tab1){ref-type="table"}). EC is diagnosed at a higher age than OC, which is reflected in the age difference seen between women with EC and those with benign tumors (Table [1](#Tab1){ref-type="table"}).Fig. 1The study design for identification of protein biomarkers using PEA

The distribution of differences in protein abundance (NPX-values) between women with OC or EC and benign tumors is shown for all proteins in Fig. [2](#Fig2){ref-type="fig"}. Proteins with a significant (Bonferroni-corrected significance threshold) difference in NPX values between benign tumors and OC (Fig. [2](#Fig2){ref-type="fig"}a--c) and between OC and EC (Fig. [2](#Fig2){ref-type="fig"}d) are labelled by name. The clinically used biomarker CA125 showed the largest differences in NPX value between OC cases and benign tumors. Nominal *p*-values for the comparisons of OC or EC with benign tumors and population controls are given for each protein in Additional file [1](#MOESM1){ref-type="media"}: Table 1.Fig. 2Distribution of differences in NPX values in the discovery step between benign tumors and OC (**a**--**c**) and between OC and EC (**d**). Only protein labels for the significant differences are shown

Employing the approach described in the methods section, 27 of the 441 proteins in the discovery analysis were selected for further evaluation. Of these, 15 proteins (PRSS8, MK, WFDC2 (HE4), IL-10, SOD2, PARP-1, hK11, PVRL4, MUC-16 (CA125), FR-alpha, CDH3, NTRK3, IL-8, IL-17C, EN-RAGE) were selected from the comparison between OC stage I--IV and benign tumors (Table [2](#Tab2){ref-type="table"}). Further, 16 proteins (PRSS8, MK, WFDC2 (HE4), IL-10, ADM, IDUA, MMP-7, FABP4, PCSK9, ST2, CTSZ, CCL16, Dkk-4, VEGF-A, IL-6, HGF) were selected from the comparison of EC with benign tumors (Table [3](#Tab3){ref-type="table"}). Four of the proteins (PRSS8, MK, WFDC2, IL-10) were selected for both OC and EC.Table 2*p*-values for the individual proteins in the discovery and replication steps in the comparison of ovarian cancer to benign tumors, population controlsUniprot noUniprot protein nameProseek Protein IDCancer typeOvarian cancer versus benign tumorsOvarian cancer versus populations controlDiscoveryReplicationDiscoveryReplicationStage I--IVStage I--IIStage III--IVStage I--IVStage I--IIStage III--IVVersus ovarian cancer stage I--IVVersus ovarian cancer stage I--IIVersus ovarian cancer stage III--IVVersus ovarian cancer stage I--IVQ16651ProstasinCVD2_173_PRSS8OE1.08E−080.4373950629.05E−113.95E−140.0018594914.83E−160.02827017811.29E−061.91E−05P21741MidkineONC2_161_MKOE2.85E−0812.73E−132.60E−080.0200680764.57E−090.00786378416.50E−111.06E−06Q14508Major epididymis-specific protein E4ONC2_182_WFDC2OE4.38E−140.0123813155.28E−171.49E−217.55E−072.68E−232.11E−0717.00E−142.35E−13P22301Interleukin-10INF_162_IL-10OE1.64E−0615.23E−100.47904697710.09729210110.004105860.5295766351P04179Superoxide dismutase \[Mn\], mitochondrialCVD2_137_SOD2O0.0006644810.0006886832.07E−090.0420297618.56E−11110.257500621.00E−05P09874Poly \[ADP-ribose\] polymerase 1CVD2_195_PARP-1O1.78E−0712.19E−113.81E−140.001922843.50E−160.21099181612.04E−070.001644308Q9UBX7Kallikrein-11ONC2_121_hK11O3.83E−0511.20E−073.72E−090.0014665442.15E−090.01160314313.43E−060.1190456Q96NY8Nectin-4ONC2_141_PVRL4O1.50E−0611.57E−092.23E−070.0965983472.39E−080.25852079611.18E−070.242568821Q8WXI7Mucin-16ONC2_191_MUC-16O9.15E−232.37E−084.49E−211.20E−160.0013020921.45E−196.59E−180.7520146149.16E−253.73E−11P15328Folate receptor alphaONC2_196_FR-alphaO3.91E−100.1154306973.90E−122.50E−180.0044820483.56E−220.00024385115.22E−091.14E−05P22223Catenin beta-1NEU_150_CDH3O3.91E−050.4844667357.72E−0510.05533485510.11813680810.0103506821Q16288NT-3 growth factor receptorNEU_190_NTRK3O0.03005557810.0397445612.31E−110.0039616831.35E−121110.015043749P10145Interleukin-8INF_101_IL-8O8.17E−0711.32E−099.27E−090.0276135549.11E−100.02790654213.41E−060.001205718Q9P0M4Interleukin-17CINF_114_IL-17CO2.51E−050.0430461880.0006897341.07E−060.0006231644.22E−061110.044912595P80511Protein S100-A12INF_175_EN-RAGEO4.87E−080.0001537017.40E−054.64E−114.81E−082.15E−090.342001882110.026901128*NA* not applicable Table 3*p*-values for the individual proteins in the discovery and replication steps in the comparison of endometrial cancer to benign tumors, population controls and ovarian cancerUniprot noUniprot protein nameProseek protein IDCancerEndometrial cancer versus benign cystsEndometrial cancer versus ovarian cancer 1--4Endometrial cancer versus population controlsDiscoveryReplicationDiscoveryReplicationDiscoveryReplicationQ16651ProstasinCVD2_173_PRSS8OE4.36E−096.88E−0813.22E−070.013810150.928202706P21741MidkineONC2_161_MKOE3.65E−080.11979541918.20E−090.0264770071Q14508Major epididymis-specific protein E4 (WAP four-disulfide core domain protein 2)ONC2_182_WFDC2OE6.28E−091.71E−1012.83E−120.2906776080.00019993P22301Interleukin 10INF_162_IL-10OE4.23E−121110.0651013251P35318AdenomedulinCVD2_103_ADME2.48E−070.0046629560.00527763915.23E−050.608471686P35475Al pha-L-iduronidaseCVD2_116_IDUAE1.05E−050.9546009366.83E−1016.52E−080.443914788P09237MatrilysinCVD2_167_MMP-7E7.21E−060.00019413310.1125286020.0013808470.000174466P15090Fatty acid-binding protein, adipocyteCVD3_129_FABP4E1.10E−0610.0126252110.0002311740.023151067Q8NBP7Proprotein convertase subtilisin/kexin type 9CVD3_161_PCSK9E1.43E−0512.42E−0510.0022078161Q01638Interleukin-1 receptor-like 1CVD3_176_ST2E1.35E−060.0102916060.02353989610.0002496950.242686447Q9UBR2Cathepsin ZCVD3_185_CTSZE3.20E−0713.59E−0612.28E−061015467C--C motif chemokine 16CVD3_196_CCL16E2.70E−0610.480038490.0064843860.0059505211Q9UBT3Dickkopf-related protein 4NEU_187_Dkk-4E2.60E−0914.27E−050.2520557490.0001340610.022042978P15692Vascular endothelial growth factor AINF_102_VEGF-AE0.001508271.88E−0614.56E−050.1562677911P05231Interleukin-6INF_113_IL-6E0.0007350481.41E−0515.49E−0611P08581Hepatocyte growth factor receptorINF_156_HGFE6.46E−056.46E−056.46E−056.46E−056.46E−050.010198277*NA* not applicable

At the highest AUC (best point analysis) the 15-protein selected for OC could distinguish women with benign tumors from those with OC stage I--IV with a sensitivity = 0.79 and specificity = 0.85 (AUC = 0.86), from OC stage I--II with a sensitivity = 0.68 and specificity = 0.73 (AUC = 0.72) and from OC stage III--IV with a sensitivity = 0.93 and specificity = 0.93 (AUC = 0.95) (Table [4](#Tab4){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}). At a minimum sensitivity of 0.95, as a cutoff value for the biomarker panel to be used as a preoperative diagnostic test, the specificity to distinguish between benign ovarian tumors and OC stage III--IV was 0.54 (Table [4](#Tab4){ref-type="table"}).Table 4Estimates of sensitivity and specificity for the protein panel based on the discovery and replication dataComparisonProteinsBest pointAUCMinimum specificity of 0.95 (screening)Minimum sensitivity of 0.95 (diagnostic)SensitivitySpecificitySensitivitySpecificitySensitivitySpecificityMeanSDMeanSDMeanSDMeanSDMeanSDMeanSD*Analysis discovery*Benign tumors versus ovarian cancer stage I--IIAll0.680.070.730.080.720.330.110.960.010.960.010.070.08Benign tumors versus ovarian cancer stage III--IVAll0.930.040.930.030.950.860.070.960.010.960.000.540.25Benign tumors versus ovarian cancer stage I--IVAll0.790.040.850.040.860.610.070.960.010.960.010.180.10Population ontrols versus ovarian cancer stage I--IIAll0.700.070.750.070.740.430.070.960.010.970.010.020.05Population controls versus ovarian cancer stage III--IVAll0.940.030.960.030.970.920.050.960.010.970.010.470.29Population controls versus ovarian stage I--IVAll0.750.050.870.050.860.660.060.950.000.960.010.130.10Benign tumors versus endometrial cancerAll0.770.050.790.050.830.450.110.960.010.970.010.090.11Population controls versus endometrial cancerAll0.690.060.780.060.760.430.070.950.000.970.010.070.07Ovarian cancer versus endometrial cancerAll0.840.040.880.040.890.640.170.970.010.960.010.420.16*Replication*Benign tumors versus ovarian cancer stage I--IIAll0.730.080.740.070.760.290.110.970.010.970.010.190.14Benign tumors versus ovarian cancer stage III--IVAll0.880.030.920.030.920.810.070.960.010.960.010.580.15Benign tumors versus ovarian cancer stage I--IVAll0.830.040.870.040.890.680.100.970.010.960.010.480.12Population ontrols versus ovarian cancer stage I--IIAll0.620.090.680.110.630.240.120.970.010.970.010.060.10Population controls versus ovarian cancer stage III--IVAll0.850.030.920.040.890.780.090.970.010.960.010.350.15Population controls versus ovarian stage I--IVAll0.770.050.850.050.860.620.100.960.010.960.010.210.11Benign tumors versus endometrial cancerAll0.700.060.670.070.720.220.090.970.010.960.010.250.08Population controls versus endometrial cancerAll0.640.070.720.080.710.240.140.970.010.960.010.100.06Ovarian cancer versus endometrial cancerAll0.730.030.770.040.780.360.060.960.000.960.000.110.06Benign tumors versus ovarian cancer stage I--IICA125/HE40.730.080.730.070.780.380.110.970.010.970.010.300.16Benign tumors versus ovarian cancer stage III--IVCA125/HE40.870.030.870.040.900.740.060.970.020.960.010.370.12Benign tumors versus ovarian cancer stage I--IVCA125/HE40.790.030.870.040.870.670.060.970.010.960.010.390.10Population ontrols versus ovarian cancer stage I--IICA125/HE40.590.080.770.100.660.350.110.970.010.970.010.140.07Population controls versus ovarian cancer stage III--IVCA125/HE40.840.030.890.040.860.740.070.970.010.960.000.170.09Population controls versus ovarian stage I--IVCA125/HE40.770.030.880.050.810.650.080.960.000.960.010.140.07 Fig. 3Reporter operator characteristic (ROC) for combinations of proteins in the discovery step. **a** Benign tumors versus Ovarian cancer stage I--II. **b** Benign tumors versus Ovarian cancer stage III--IV. **c** Benign tumors versus Ovarian cancer stage I--IV. **d** Population controls versus Ovarian cancer stage I--II. **e** Population controls versus Ovarian cancer stage III--IV. **f** Population controls versus Ovarian cancer stage I--IV. **g** Benign tumors versus Endometrial cancer. **h** Controls versus Endometrial cancer. **i** Ovarian cancer stage I-IV versus endometrial cancer versus

The 15-protein panel was also able to distinguish population controls from OC stage I--IV with a sensitivity = 0.75 and specificity = 0.87 (AUC = 0.86), from OC stage I--II with a sensitivity = 0.70 and specificity = 0.75 (AUC = 0.74) and from OC stage III--IV with a sensitivity = 0.94 and specificity = 0.96 (AUC = 0.97) (Table [4](#Tab4){ref-type="table"}). At a specificity of 0.96, as a cutoff value for the biomarker panel to be useful in population screening, the sensitivity to distinguish controls from OC stage I--IV was 0.66, from OC stage I--II it was 0.43 and from OC stage III--IV it was 0.92 (Table [4](#Tab4){ref-type="table"}).

Since plasma samples from benign tumors and OC stage I--IV had been analyzed previously for CA125 we compared our CA125 values from PEA with those from the Architect CA125-II assay (Abbott Diagnostics, Abbott Park, IL, USA). There was a strong correlation between the two measurements (*R*^2^ = 0.87, *p* value \< 6.72e−128), except for the highest values which were outside the linear part of the range for PEA (Fig. [4](#Fig4){ref-type="fig"}, Additional file [2](#MOESM2){ref-type="media"}: Table 2).Fig. 4Correlation between CA125 values from the multiplex PEA used in the discovery step and from clinical ELISA, for benign tumors (in black) and ovarian cancer patients (in red)

For EC the 16-protein panel distinguished benign tumors from EC with a sensitivity = 0.77 and specificity = 0.79 (AUC = 0.83). OC stage I--IV could be distinguished from EC with a sensitivity of 0.84 and specificity of 0.88 (AUC = 0.89). Finally, the EC patients could be distinguished from population controls with a sensitivity = 0.69 and specificity = 0.78 (AUC = 0.76) (Table [4](#Tab4){ref-type="table"}).

Replication step {#Sec9}
----------------

Two focused multiplex PEA assays were developed for the 27 proteins identified in the discovery step, according to the protocol described by the manufacturer \[[@CR15]\]. There was excellent correlation between the protein estimates from the multiplex assays used in the discovery step and the focused PEA assays used in the replication step (Fig. [5](#Fig5){ref-type="fig"}). Despite absolute differences in NPX-values (as expected since the dynamic range was shifted for some assays in the custom panel) the rank of different proteins was maintained (Fig. [5](#Fig5){ref-type="fig"}). Average intra- and interassay CV for 17 of the proteins included in the discovery and replication assays have previously been shown to be similar to the Olink's commercial 92-plex screening panels \[[@CR15]\]. Thus, the results of the PEA analyses used in the discovery and the replication steps were considered comparable.Fig. 5Correlation in protein abundance between the 92-plex panels and the focused protein panels for the six proteins **a** CA125, **b** IL10, **c** ENRAGE, **d** HE4, **e** MK, **f** Dkk4

The focused PEA panels were then used to study an independent set of plasma samples from women with either of the two cancers, benign tumors and population controls (Table [1](#Tab1){ref-type="table"}). For OC, the association was replicated for 13 of the 15 proteins and only IL-10 and CDH3 showed no association with OC. The protein panel distinguished benign tumors from OC stage I--IV with a sensitivity = 0.83 and specificity = 0.87 (AUC = 0.89), from OC stage I--II with a sensitivity = 0.73 and specificity = 0.74 (AUC = 0.76) and from OC stage III--IV with a sensitivity = 0.88 and specificity = 0.92 (AUC = 0.92) (Table [4](#Tab4){ref-type="table"}, Fig. [6](#Fig6){ref-type="fig"}). The protein panel selected for OC had a significantly higher AUC than using only CA125 and HE4 for distinguishing benign tumors from OC (stage I--IV, *p *= 1.41e−13; stage 3--4, *p *= 9.56e−22). At a sensitivity of 0.96, the specificity to distinguish between benign ovarian tumors and OC stage I--IV was 0.48, stage I--II it was 0.19 and stage III--IV it was 0.58 (Table [4](#Tab4){ref-type="table"}).Fig. 6Reporter operator characteristic (ROC) for combinations of proteins in replication stage. The blue line is using CA125 and HE4 only. **a** Benign tumors versus Ovarian cancer stage I--II. **b** Benign tumors versus Ovarian cancer stage III--IV. **c** Benign tumors versus Ovarian cancer stage I--IV. **d** Population controls versus Ovarian cancer stage I--II. **e** Population controls versus Ovarian cancer stage III--IV. **f** Population controls versus Ovarian cancer stage I--IV. **g** Benign tumors versus Endometrial cancer. **h** Controls versus Endometrial cancer. **i** Ovarian cancer stage I--IV versus endometrial cancer versus

The selected protein panel distinguished population controls from OC stage I--IV with a sensitivity = 0.77 and specificity = 0.85 (AUC = 0.86), from OC stage I--II with a sensitivity = 0.62 and specificity = 0.68 (AUC = 0.63), and from OC stage III--IV with a sensitivity = 0.85 and specificity = 0.92 (AUC = 0.89) (Table [4](#Tab4){ref-type="table"}, Fig. [6](#Fig6){ref-type="fig"}). At a minimum specificity of 0.95, the sensitivity to distinguish population controls from OC stage I--IV was 0.62, from OC stage I--II it was 0.24, and from OC stage III--IC it was 0.78 (Table [4](#Tab4){ref-type="table"}).

In a recent study, candidate biomarkers for OC were identified using the Olink Multiplex ONC I v2 panel \[[@CR5]\]. That panel is discontinued by the manufacturer and replaced by the ONC II panel used here. However, some of the proteins overlap with the panels used here, and we therefore compared the AUC values for these proteins in the two studies (Fig. [7](#Fig7){ref-type="fig"}a). There was good correlation in the comparison of benign tumors to OC stage III--IV, but the AUC values were generally higher in the study by Boylan et al. \[[@CR5]\]. By contrast, no correlation was found in the AUC values when comparing benign tumors and OC stage I--II (Fig. [7](#Fig7){ref-type="fig"}b).Fig. 7Correlation between AUC values for some of the proteins overlapping between our study and that by Boylan et al. \[[@CR5]\] for the comparison between benign tumors and ovarian cancer stage III--IV (left panel) and I--II (right panel)

Of the 16 proteins selected for EC, an association was replicated for nine (PRSS8, MK, WFDC2 (HE4), ADM, MMP-7, ST2, VEGF-A, IL-6, HGF), while seven proteins showed no association (IL-10, IDUA, FABP-4, PCSK9, CTSZ, CCL16, Dkk-4). The protein panel distinguished between benign tumors and EC with a sensitivity = 0.70 and a specificity = 0.67 (AUC = 0.72). Population controls could be distinguished from EC with a sensitivity = 0.64 and specificity = 0.72 (AUC = 0.71).

Of the 13 proteins that differed significantly between OC stage I--IV and EC in the discovery data, six (hK11, MUCIN-16, FR-alpha, NTRK3, EN-RAGE, HGF) showed a significant difference in the replication step (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}). OC stage I--IV could be distinguished from EC with a sensitivity = 0.73 and a specificity = 0.77 (AUC = 0.78).

Discussion {#Sec10}
==========

We have searched for plasma proteins that could distinguish between patients with the gynecologic cancers OC and EC and benign tumors, using a two-step study design and a scalable technology for measuring protein abundance. The high degree of multiplexing of PEA panels enabled us to screen 441 unique proteins in search of suitable biomarker candidates. The ability to scale the PEA technology was then used to design two focused multiplex panels for the proteins selected in the discovery step. The abundance estimates for the proteins measured both in discovery step and the replication step showed high correlation and similar precision, testifying to that the PEA technology is scalable without compromising the performance for detection of individual proteins. In fact, by using a smaller Integrated Fluidic Circuit for the analysis, we were able to combine PEA assays for proteins with a greater difference in abundance than is possible using the 92-protein Integrated Fluidic Circuits.

Proteins identified {#Sec11}
-------------------

Among the proteins we identified as biomarker candidates for OC some have been discussed previously \[[@CR5]\], such as Mucin-16 (CA125) and Major epididymis-specific protein E4 (HE4), Midkine (MK) \[[@CR16], [@CR17]\], Kallikrein-11 (hK11) \[[@CR18]\], Folate receptor alpha (FR) \[[@CR19], [@CR20]\] and Prostasin (PRSS8) \[[@CR21], [@CR22]\]. Boylan et al. \[[@CR5]\] also using PEA technology further reported an association of OC with Interleukin-6 (IL-6) \[[@CR23]--[@CR25]\], Kallikrein-6 (KLK6) \[[@CR26]\], Furin (FUR) \[[@CR27]\], Chemokine (C-X-C motif) ligand 13 (CXCL13) and Tumor necrosis factor ligand superfamily member 14 (TNFSF14), but none of these proteins were among our top candidates. A number of the proteins we selected for the replication step were not studied by Boylan et al. \[[@CR5]\] such as Interleukin-8 (IL-8), Nectin-4 (PVRL4), Interleukin-17C (IL17C), Poly (ADP-ribose) polymerase-1 (PARP-1), Superoxide dismutase (Mn), mitochondrial (SOD2) and Protein S100-A12 (EN-RAGE). Several of these have previously been noted in connection to OC. The level of Interleukin-8 has been proposed as a diagnostic and prognostic biomarker for OC \[[@CR28]--[@CR30]\]. Nectin-4 is overexpressed in epithelial cancers including OC and has been proposed as a therapeutic target \[[@CR31]\]. Interleukin-17C has been shown to be tumor-promoting in OC cell models \[[@CR32]\]. Poly (ADP-ribose) polymerase 1 is overexpressed in OC and may enhance angiogenesis by upregulating Vascular endothelial growth factor A (VEGF-A) \[[@CR33]\]. Genetic variation in Neurotrophic tyrosine receptor kinase 3 (NTRK3) has been associated with prognosis of OC and suggested to predict platinum resistance in OC patients \[[@CR34]\]. Superoxide dismutase (Mn), mitochondrial, is highly expressed in OC and has been shown to increase tumor development and metastatic spread \[[@CR35]\].

Among the nine proteins (Prostasin (PRSS8), Midkine (Mk), Major epididymis-specific protein E4 (HE4), Adenomedulin (ADM), Matrilysin (MMP-7), Interleukin-1 receptor-like 1 (ST2), Vascular endothelial growth factor A (VEGF-A), Interleukin-6 (IL-6), Hepatocyte growth factor receptor (HGF)) associated with EC in the replication step, several have been discussed in relation to EC. Midkine has been proposed as a serum biomarker for high-risk EC patients, and preoperative serum levels have been shown to correlate with lymph node metastasis \[[@CR36]\]. Adrenomedullin expression is upregulated in post-menopausal endometria, and is increased during progression from benign endometrium to type-1 adenocarcinoma \[[@CR37], [@CR38]\]. Fatty acid-binding protein (FABP4) has been proposed as a diagnostic biomarker for EC \[[@CR39], [@CR40]\] and showed a significant association in our discovery step analysis, but not in the replication step.

Preoperative diagnostic {#Sec12}
-----------------------

Our protein panel has a sensitivity = 0.83 and specificity = 0.87 to distinguish between benign tumors and OC stage I--IV. The specificity of our protein panel is somewhat lower than the 0.91 of Overa^®^, while the sensitivity is higher than the 0.69 reported for Overa^®^ \[[@CR4]\]. Focusing on OC stage III--IV we have a sensitivity = 0.88 and specificity = 0.92, which is significantly higher than using only CA125 and HE4.

A test for triaging women with adnexal ovarian mass should have better performance than TVU. A recent study showed that TVU in the hands of specially trained gynecologic sonographers can achieve an AUC = 0.92 \[[@CR41]\]. However, the performance of ordinary gynecologists is generally lower. For instance, among women with a TVU indication of adnexal ovarian mass that are diagnosed by surgical sampling, 58% have been reported to have benign tumors, 30% have OC stage I--IV and the remaining 15% borderline tumors \[[@CR42], [@CR43]\]. Among the 30% of women with OC, 15% have OC stage III--IV. Based on these estimates, clinical diagnosis by surgical sampling has a specificity for OC stage I--IV of 0.30 and for OC III--IV of 0.15. At a minimum sensitivity of 0.96, used as a threshold for a preoperative diagnostic test, our protein panel can distinguish between benign tumors and OC stage III--IV with a specificity of 0.58. This indicates that the number of women with OC stage III--IV among those stratified for surgical sampling based on TVU could be increased from 15% when using TVU to 58% by using the protein panel. For OC stage I--IV, the protein panel show a specificity of 0.48, while the specificity of TVU is 0.30. This correspond to a 50% increase of the specificity. The combined use of both TVU and the biomarker test is likely to give even higher specificity.

Boylan et al. \[[@CR5]\] used the ONC Iv2 panel to search for candidate biomarkers for OC. Several of the proteins found to be associated with OC in their study were also on our list of candidates, such as Major epididymis-specific protein E4, Midkine, Kallikrein-11, Folate receptor alpha. Interleukin-6, and Prostasin. Their list of top proteins had consistently higher AUC values than our estimates (Fig. [7](#Fig7){ref-type="fig"}). This may reflect differences in design between the studies. Boylan et al. \[[@CR5]\] used a single set of cases and controls for identification of proteins, while we used a two-step analysis with two independent set of clinical materials, and in the replication step we also included OC patients from two different hospitals. Our study thus includes several factors that could introduce variation, such as multiple patient cohorts from both the same and different hospitals, different PEA analysis rounds and using both 92-plex and focused PEA panels, and finally the use of a replication step to verify initial findings. Together these factors are likely to reduce the overall performance characteristics of the assay, while at the same time result in more realistic performance indicators.

We also identified a set of protein biomarkers that can be used to distinguish between benign tumors and EC. Biomarkers have previously been described for EC, and good diagnostic accuracy has been reported for e.g. Major epididymis-specific protein E4 (HE4), Growth/differentiation factor 15 (GDF-15), C-Jun-amino-terminal kinase-interacting protein 4 (JIP-4), JNK-interacting protein 4 (SPAG9), Chitinase-3-like protein 1 (YKL-40), Interleukin-31 (IL-31) and Interleukin-33 (IL-33) \[[@CR11]\]. Further studies are needed to compare the performance of these candidates with the ones identified in the present study.

Population screening {#Sec13}
--------------------

Our results indicate that the focused protein panel at a specificity of 0.96 has a high sensitivity to distinguish population controls from women with OC stage I--IV and stage III--IV, while lower for stage I--II. To determine the potential of using the protein panel in population screening, further studies are needed of based on samples collected at distinct time-points prior to diagnosis. A recent evaluation of four markers (CA125, HE4, CA72.4, and CA15.3) for OC showed that the performance declined with increasing time between sample collection and time of diagnosis \[[@CR44]\]. Serial sampling could enable the use of individual baseline values, and testing women at 3 months rather than 6-12-month intervals using ROCA has been shown to result in better sensitivity and high specificity for detection of early-stage disease \[[@CR45]\].

In summary, we have used a two-step strategy to identify plasma proteins that can be used to distinguish benign tumors from OC or EC and for differential diagnostic procedures of women with suspicious pelvic mass. The biomarker panels could be useful in population screening and to identify women in need of TVU examination at a specialized gynecologic ultrasound unit.
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